DE69531458D1 - Chinolinderivate als tachykinin nk3 rezeptor antagonisten - Google Patents

Chinolinderivate als tachykinin nk3 rezeptor antagonisten

Info

Publication number
DE69531458D1
DE69531458D1 DE69531458T DE69531458T DE69531458D1 DE 69531458 D1 DE69531458 D1 DE 69531458D1 DE 69531458 T DE69531458 T DE 69531458T DE 69531458 T DE69531458 T DE 69531458T DE 69531458 D1 DE69531458 D1 DE 69531458D1
Authority
DE
Germany
Prior art keywords
tachykinin
receptor antagonists
chinoline derivatives
chinoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69531458T
Other languages
English (en)
Other versions
DE69531458T2 (de
Inventor
Carlo Farina
Giuseppe A M Giardina
Mario Grugni
Francesco Raveglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Smithkline Beecham Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/it
Priority claimed from ITMI950494 external-priority patent/IT1293558B1/it
Application filed by Smithkline Beecham Farmaceutici SpA filed Critical Smithkline Beecham Farmaceutici SpA
Publication of DE69531458D1 publication Critical patent/DE69531458D1/de
Application granted granted Critical
Publication of DE69531458T2 publication Critical patent/DE69531458T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
DE69531458T 1994-05-27 1995-05-23 Chinolinderivate als tachykinin nk3 rezeptor antagonisten Expired - Lifetime DE69531458T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI941099 1994-05-27
IT94MI001099A ITMI941099A1 (it) 1994-05-27 1994-05-27 Derivati chinolinici
ITMI950494 1995-03-14
ITMI950494 IT1293558B1 (it) 1995-03-14 1995-03-14 Derivati chinolinici
PCT/EP1995/002000 WO1995032948A1 (en) 1994-05-27 1995-05-23 Quinoline derivatives as tachykinin nk3 receptor antagonists

Publications (2)

Publication Number Publication Date
DE69531458D1 true DE69531458D1 (de) 2003-09-11
DE69531458T2 DE69531458T2 (de) 2004-08-05

Family

ID=26331143

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69533408T Expired - Lifetime DE69533408T2 (de) 1994-05-27 1995-05-23 Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
DE69531458T Expired - Lifetime DE69531458T2 (de) 1994-05-27 1995-05-23 Chinolinderivate als tachykinin nk3 rezeptor antagonisten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69533408T Expired - Lifetime DE69533408T2 (de) 1994-05-27 1995-05-23 Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten

Country Status (35)

Country Link
US (5) US6608083B1 (de)
EP (2) EP0940391B1 (de)
JP (5) JP3664492B2 (de)
KR (1) KR100316571B1 (de)
CN (3) CN1092642C (de)
AP (1) AP578A (de)
AR (1) AR037069A2 (de)
AT (2) ATE273959T1 (de)
AU (1) AU699319B2 (de)
BG (2) BG64004B1 (de)
BR (1) BR9507788A (de)
CA (1) CA2191352C (de)
CZ (1) CZ291476B6 (de)
DE (2) DE69533408T2 (de)
DK (1) DK0804419T3 (de)
DZ (1) DZ1889A1 (de)
ES (2) ES2227769T3 (de)
FI (2) FI115052B (de)
HK (2) HK1003884A1 (de)
HU (1) HU226535B1 (de)
IL (1) IL113844A (de)
MA (1) MA23560A1 (de)
MX (1) MX9605903A (de)
MY (1) MY129596A (de)
NO (2) NO307783B1 (de)
NZ (1) NZ287442A (de)
OA (1) OA10592A (de)
PL (2) PL186075B1 (de)
PT (2) PT940391E (de)
RO (1) RO114445B1 (de)
SA (1) SA95160290B1 (de)
SK (2) SK282722B6 (de)
TW (2) TW533199B (de)
UA (1) UA51623C2 (de)
WO (1) WO1995032948A1 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282722B6 (sk) * 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. N-(alfa-Etylbenzyl)-3-hydroxy-2-fenylchinolín-4-karboxamid, farmaceutický prípravok s jeho obsahom a jeho použitie
NZ323387A (en) * 1995-11-24 2000-02-28 Smithkline Beecham Spa Quinoline derivatives having neurokinin antagonist activity, preparation and use thereof
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU757836B2 (en) * 1995-11-24 2003-03-06 Smithkline Beecham Spa Quinoline derivatives
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
EP1491533A3 (de) * 1997-03-14 2005-01-19 Cephalon, Inc. Chinolin- und Naphthalincarboxamide, deren pharmazeuitische Zubereitungen und Verwendung als Calpain Inhibitoren
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
ID22876A (id) * 1997-05-23 1999-12-16 Smithkline Beecham Spa Turunan quinolin-4-karboksamida sebagai penerima antagonis nk-2 dan nk-3
US20010012846A1 (en) * 1997-05-23 2001-08-09 Glardina Giuseppe Arnaldo Maria Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
EP1652840A3 (de) * 1997-09-17 2006-05-17 Smithkline Beecham Corporation (-)-(S)-N-(.alpha.-Ethylbenzyl)-3-hydroxy-2-phenylchinolin-4-carboxamid
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
GB9825554D0 (en) 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
BR9915475A (pt) * 1998-11-20 2001-12-18 Smithkline Beecham Spa Derivados da quinolina-4-carboxamida comoantagonistas dos receptores de nk-3 e nk-2
US6780875B2 (en) * 1998-11-20 2004-08-24 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
JP2002535274A (ja) * 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション 抗アンドロゲン剤および疾病の治療方法
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
WO2000058303A1 (en) 1999-03-29 2000-10-05 Neurogen Corporation 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2002013825A1 (en) * 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
WO2002083663A1 (en) * 2001-04-11 2002-10-24 Glaxosmithkline S.P.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
WO2004002484A1 (ja) * 2002-06-26 2004-01-08 Kyowa Hakko Kogyo Co., Ltd. ホスホジエステラーゼ阻害剤
GB0228288D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228287D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
WO2005061545A2 (en) 2003-12-22 2005-07-07 Glaxo Group Limited Nogoa antibodies for the treatment of alzheimer disease
KR100799802B1 (ko) 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
JP2007530591A (ja) * 2004-03-25 2007-11-01 スミスクライン・ビーチャム・コーポレイション 双極性障害を治療するための、ｎｋ３アンタゴニストの使用
DK1729734T3 (da) * 2004-03-30 2008-06-16 Smithkline Beecham Corp Spröjtetörrede farmaceutiske præparater
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
GB0417559D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0417560D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0425076D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
US20080200500A1 (en) * 2005-06-03 2008-08-21 Astrazeneca Ab Quinoline Derivatives as Nk3 Antagonists
MX2007015607A (es) * 2005-06-23 2008-02-25 Astrazeneca Ab Esteres de quinolin 3-sulfonato como moduladores del receptor de nk3.
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
EP1919871A4 (de) * 2005-08-02 2010-08-18 Glaxosmithkline Llc Verfahren zur synthese von chinolinderivaten
CN101282964A (zh) * 2005-08-11 2008-10-08 阿斯利康(瑞典)有限公司 作为nk3受体调节剂的氧-吡啶基喹啉酰胺
WO2007018465A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Amide alkyl pyridiyl quinolines as nk3 receptor modulators
AR057130A1 (es) 2005-09-21 2007-11-14 Astrazeneca Ab Quinolinas de alquilsulfoxido y una composicion farmaceutica
EP1940795A1 (de) * 2005-09-21 2008-07-09 AstraZeneca AB N-oxo-heterocyclyl- und n-oxo-alkylchinolin-4-carbonsäureamide als liganden des nk-3-rezeptors
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
WO2007075901A2 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP1981882A4 (de) * 2006-01-27 2009-11-18 Astrazeneca Ab Amidsubstituierte chinoline
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
AR065806A1 (es) 2007-03-22 2009-07-01 Astrazeneca Ab Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea.
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
EP2188260A1 (de) * 2007-08-22 2010-05-26 Allergan, Inc. Therapeutische chinolin- und naphthalinderivate
WO2009049791A2 (en) * 2007-10-15 2009-04-23 F. Hoffmann-La Roche Ag Radiolabeled nk3 receptor antagonist
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
AR072198A1 (es) * 2008-06-23 2010-08-11 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
CN102256948A (zh) 2008-10-20 2011-11-23 H.隆德贝克有限公司 用作nk3拮抗剂的异喹啉酮衍生物
EP2408750B1 (de) 2009-03-20 2015-08-26 Vertex Pharmaceuticals Incorporated Verfahren zur herstellung von modulatoren des cystic fibrosis transmembrane conductance-regulators
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2804859B1 (de) * 2012-01-17 2019-06-12 Universiteit Antwerpen Neuartige fap-inhibitoren
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
CN102702099A (zh) * 2012-06-21 2012-10-03 江苏恩华药业股份有限公司 (s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法
BR112015026519A2 (pt) 2013-04-19 2017-07-25 Astrazeneca Ab composto antagonista do receptor nk3 (nk3ra) para uso em um método destinado ao tratamento de síndrome do ovário policístico (sop)
US10314835B2 (en) 2014-06-25 2019-06-11 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
WO2016004035A1 (en) * 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases
US10189788B2 (en) 2014-09-09 2019-01-29 Bayer Pharma Aktiengesellschaft Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
MX370450B (es) 2014-10-07 2019-12-13 Vertex Pharma Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
US10117864B2 (en) 2015-03-18 2018-11-06 Bayer Pharma Aktiengesellschaft Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
MX2017012720A (es) * 2015-05-18 2018-02-09 Nerre Therapeutics Ltd Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2017153235A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung
WO2017153231A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
WO2017153234A1 (de) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
US11136296B2 (en) * 2017-04-10 2021-10-05 Bayer Aktiengesellschaft Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (zh) 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
WO2019090001A1 (en) 2017-11-02 2019-05-09 California Institute Of Technology Neurokinin antagonists and uses thereof
US20210401821A1 (en) * 2018-11-15 2021-12-30 Kyushu University, National University Corporation Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1560489A (en) * 1976-05-21 1980-02-06 Fisons Ltd Pharmaceutical compositions
FR2538388B1 (fr) 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
DE3905339A1 (de) * 1989-02-22 1990-09-06 Basf Ag Chinolin-4-carbonsaeurederivate und deren verwendung
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US5037835A (en) * 1989-10-24 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
DE69126058T2 (de) * 1990-03-26 1997-09-25 Matsushita Electric Ind Co Ltd Lichtempfindliches Material für Elektrophotographie
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
SK282722B6 (sk) 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. N-(alfa-Etylbenzyl)-3-hydroxy-2-fenylchinolín-4-karboxamid, farmaceutický prípravok s jeho obsahom a jeho použitie
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists

Also Published As

Publication number Publication date
DZ1889A1 (fr) 2002-02-17
ATE246677T1 (de) 2003-08-15
HUT76286A (en) 1997-07-28
SK282721B6 (sk) 2002-11-06
PT804419E (pt) 2003-12-31
CZ291476B6 (cs) 2003-03-12
FI990268A (fi) 1999-02-10
CA2191352C (en) 2001-01-30
JPH10500697A (ja) 1998-01-20
RO114445B1 (ro) 1999-04-30
FI990268A0 (fi) 1999-02-10
CA2191352A1 (en) 1995-12-07
BG103181A (bg) 1999-09-30
US6608083B1 (en) 2003-08-19
CN1156451A (zh) 1997-08-06
NO965036D0 (no) 1996-11-26
US20030236281A1 (en) 2003-12-25
NO991813D0 (no) 1999-04-16
HU226535B1 (en) 2009-03-30
AP9500745A0 (en) 1995-07-31
HU9603262D0 (en) 1997-01-28
FI115052B (fi) 2005-02-28
DE69531458T2 (de) 2004-08-05
OA10592A (en) 2002-08-27
CN1092642C (zh) 2002-10-16
JP3664492B2 (ja) 2005-06-29
UA51623C2 (uk) 2002-12-16
AU2616495A (en) 1995-12-21
EP0940391A2 (de) 1999-09-08
MX9605903A (es) 1998-08-30
FI964712A (fi) 1997-01-23
IL113844A (en) 2005-05-17
SK151496A3 (en) 1997-07-09
AR037069A2 (es) 2004-10-20
US5811553A (en) 1998-09-22
FI964712A0 (fi) 1996-11-26
MY129596A (en) 2007-04-30
HK1003884A1 (en) 1998-11-13
CZ347096A3 (en) 1997-10-15
WO1995032948A1 (en) 1995-12-07
MA23560A1 (fr) 1995-12-31
SK282722B6 (sk) 2002-11-06
PL317381A1 (en) 1997-04-01
AU699319B2 (en) 1998-12-03
BG64004B1 (bg) 2003-09-30
HK1024469A1 (en) 2000-10-13
JP2005068155A (ja) 2005-03-17
SK4799A3 (en) 1999-06-11
US20050096316A1 (en) 2005-05-05
PL186075B1 (pl) 2003-10-31
PT940391E (pt) 2004-12-31
TW533199B (en) 2003-05-21
DK0804419T3 (da) 2003-11-24
JP2002179594A (ja) 2002-06-26
KR100316571B1 (ko) 2002-05-30
EP0940391B1 (de) 2004-08-18
NZ287442A (en) 1998-05-27
NO965036L (no) 1997-01-24
NO326714B1 (no) 2009-02-02
EP0804419B1 (de) 2003-08-06
NO307783B1 (no) 2000-05-29
US20060160846A1 (en) 2006-07-20
JP2007126475A (ja) 2007-05-24
EP0940391A3 (de) 1999-11-10
FI119721B (fi) 2009-02-27
US7482458B2 (en) 2009-01-27
DE69533408D1 (de) 2004-09-23
CN1428145A (zh) 2003-07-09
TW427977B (en) 2001-04-01
AP578A (en) 1997-03-26
DE69533408T2 (de) 2005-09-08
SA95160290B1 (ar) 2006-06-21
NO991813L (no) 1997-01-24
ES2204952T3 (es) 2004-05-01
EP0804419A1 (de) 1997-11-05
JP2000026314A (ja) 2000-01-25
SA95160290A (ar) 2005-12-03
BG101008A (en) 1997-08-29
IL113844A0 (en) 1995-08-31
BR9507788A (pt) 1997-09-23
ATE273959T1 (de) 2004-09-15
ES2227769T3 (es) 2005-04-01
PL186665B1 (pl) 2004-02-27
CN1276211A (zh) 2000-12-13

Similar Documents

Publication Publication Date Title
DE69531458D1 (de) Chinolinderivate als tachykinin nk3 rezeptor antagonisten
DE69728392D1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
DE69531331D1 (de) Phenylpiperidinderivate als neurokinin antagonists
NO951613D0 (no) Ikke-peptidyl tachykinin reseptorantagonister
DE69431604D1 (de) Benzofuranderivate als tachykininantagonisten
DE69628334D1 (de) Chinolin derivate als nk3 antagoniste
ID19623A (id) Antagonis reseptor vitronektin
DE69127791T2 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
DE69714265D1 (de) Tetrahydrochinolinderivate als eaa antagonisten
DE69626220D1 (de) 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
DE69626416T2 (de) Salze von chinolinderivaten als nk3 antagonisten
DE69703242T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
ID24468A (id) 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
DE69735811D1 (de) Piperazinoderivate als neurokinin-antagonisten
DE69717449T2 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten
ATE206421T1 (de) Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten
DE69617010T2 (de) Isazole derivate als fibrinogen-rezeptor-antagonisten
ID24309A (id) 2-asilaminopropanamina sebagai antagonis reseptor tachykinin
DE69714019D1 (de) 1,4-dihydropyridin-verbindungen als bradykinin-antagonisten
DK0940391T3 (da) Quinolinderivater som tachykinin-NK3-receptor-antagonister
SI0940391T1 (en) Quinoline derivatives as tachykinin NK3 receptor antagonists

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GLAXOSMITHKLINE S.P.A., VERONA, IT

8328 Change in the person/name/address of the agent

Representative=s name: VOSSIUS & PARTNER, 81675 MUENCHEN

8364 No opposition during term of opposition